BBI608: Phase III discontinued

Dainippon discontinued the double-blind, placebo-controlled, international Phase III CO.23 trial evaluating twice-daily 480 mg BBI608 plus best supportive

Read the full 184 word article

How to gain access

Continue reading with a
two-week free trial.